Regulatory T Cells and Cancer: A Two-Sided Story

References

• Akhurst RJ, Derynck, R. (2001). TGF-beta signaling in cancer–a double-edged sword. Trends Cell Biol, 11(11), S44S51.
   Web of Science ®Google Scholar
• Arico S, Pattingre S, Bauvy C, et al. (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem, 277(31), 27613–27621.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504(7480), 451–455.
   PubMed Web of Science ®Google Scholar
• Attisano L, Wrana JL. (2002). Signal transduction by the TGF-beta superfamily. Science, 296(5573), 1646–1647.
   PubMed Web of Science ®Google Scholar
• Azzam HS, DeJarnette JB, Huang K, et al. (2001). Fine tuning of TCR signaling by CD5. J Immunology, 166(9), 5464–5472.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539–545.
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Schramm C, et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21(4), 491–501.
   PubMed Web of Science ®Google Scholar
• Beissert S, Schwarz T. (1999). Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc, 4(1), 61–64.
   PubMedGoogle Scholar
• Bennett CL, Christie J, Ramsdell F, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27(1), 20–21.
   PubMed Web of Science ®Google Scholar
• Berg DJ, Davidson N, Kuhn R, et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest, 98(4), 1010–1020.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441(7090), 235–238.
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Chytil A, Plieth D, et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303(5659), 848–851.
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332–337.
   PubMed Web of Science ®Google Scholar
• Bollrath J, Phesse TJ, von Burstin VA, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15(2), 91–102.
   PubMed Web of Science ®Google Scholar
• Bopp T, Becker C, Klein M, et al. (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med, 204(6), 1303–1310.
   PubMed Web of Science ®Google Scholar
• Borsellino G, Kleinewietfeld M, Di Mitri D, et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 110(4), 1225–1232.
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27(1), 68–73.
   Google Scholar
• Burchill M.A, Yang J, Vogtenhuber C, et al. (2007). IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol, 178(1), 280–290.
   PubMed Web of Science ®Google Scholar
• Calon A, Espinet E, Palomo-Ponce S, et al. (2012). Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell, 22(5), 571–584.
   PubMed Web of Science ®Google Scholar
• Carter JD, Calabrese GM, Naganuma M, Lorenz U. (2005). Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. J Immunol, 174(11), 6627–6638.
   PubMed Web of Science ®Google Scholar
• Chatila TA, Blaeser F, Ho N, et al. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest, 106(12), R75–81.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Samstein RM, Treuting P, et al. (2011). Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity, 34(4), 566–578.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 13(4), 227–242.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, et al. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198(12), 1875–1886.
   PubMed Web of Science ®Google Scholar
• Chen WS, Liu JH, Wei SJ, et al. (2003). Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci, 94(3), 253–258.
   PubMed Web of Science ®Google Scholar
• Cho ML, Kang JW, Moon YM, et al. (2006). STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol, 176(9), 5652–5661.
   PubMed Web of Science ®Google Scholar
• Choi PM, Zelig MP. (1994). Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut, 35(7), 950–954.
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, et al. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450(7169), 566–569.
   PubMed Web of Science ®Google Scholar
• Correa P, Pickle LW, Fontham E, et al. (1983). Passive smoking and lung cancer. Lancet, 2(8350), 595–597.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420(6917), 860–867.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA, 107(9), 4275–4280.
   PubMed Web of Science ®Google Scholar
• Dasu T, Qualls JE, Tuna H, et al. (2008). CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett, 119(1–2), 103–113.
   PubMed Web of Science ®Google Scholar
• Davidson NJ, Leach MW, Fort MM, et al. (1996). T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med, 184(1), 241–251.
   PubMed Web of Science ®Google Scholar
• Davis MM, Bjorkman PJ. (1988). T-cell antigen receptor genes and T-cell recognition. Nature, 334(6181), 395–402.
   PubMed Web of Science ®Google Scholar
• Dennis KL, Wang Y, Blatner NR, et al. (2013). Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res, 73(19), 5905–5913.
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29(2), 117–129.
   PubMed Web of Science ®Google Scholar
• de Visser KE, Eichten A, Coussens LM. (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6(1), 24–37.
   PubMed Web of Science ®Google Scholar
• DiDonato JA, Mercurio F, Karin M. (2012). NF-kappaB and the link between inflammation and cancer. Immunol Rev, 246(1), 379–400.
   PubMed Web of Science ®Google Scholar
• Doll R. (1993). Mortality from lung cancer in asbestos workers 1955. Br J Ind Med, 50(6), 485–490.
   PubMedGoogle Scholar
• Doll R, Hill AB. (1956). Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J, 2(5001), 1071–1081.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 3(11), 991–998.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48(4), 526–535.
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. (1990a). Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet, 336(8711), 357–359.
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. (1990b). Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med, 323(18), 1228–1233.
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer, 13(11), 759–771.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(6), 1264–1273 e1261.
   PubMed Web of Science ®Google Scholar
• Erdman SE, Poutahidis T, Tomczak M, et al. (2003). CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol, 162(2), 691–702.
   PubMed Web of Science ®Google Scholar
• Erdman SE, Rao VP, Poutahidis T et al. (2003). CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res, 63(18), 6042–6050.
   PubMed Web of Science ®Google Scholar
• Erdman SE, Sohn JJ, Rao VP, et al. (2005). CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res, 65(10), 3998–4004.
   PubMed Web of Science ®Google Scholar
• EUROGAST Study Group. (1993). An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341(8857), 1359–1362.
   PubMedGoogle Scholar
• Fehervari Z, Sakaguchi S. (2004). Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol, 16(2), 203–208.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Mosmann TR, et al. (1991). IL-10 inhibits cytokine production by activated macrophages. J Immunol, 147(11), 3815–3822.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Vieira P, et al. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol, 146(10), 3444–3451.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4), 330–336.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. (2005). A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 6(11), 1142–1151.
   PubMed Web of Science ®Google Scholar
• Friedline RH, Brown DS, Nguyen H, et al. (2009). CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med, 206(2), 421–434.
   PubMed Web of Science ®Google Scholar
• Furusawa Y, Obata Y, Fukuda S, et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446–450.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yang W, Pan M, et al. (2003). Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med, 198(3), 433–442.
   PubMed Web of Science ®Google Scholar
• Glick AB. (2012). The role of TGFbeta signaling in squamous cell cancer: Lessons from mouse models. J Skin Cancer, 2012, 249063.
   PubMedGoogle Scholar
• Go C, Li P, Wang XJ. (1999). Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res, 59(12), 2861–2868.
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Drake CG. (2011). LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol, 344, 269–278.
   PubMed Web of Science ®Google Scholar
• Gondek DC, Lu LF, Quezada SA, et al. (2005). Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol, 174(4), 1783–1786.
   PubMed Web of Science ®Google Scholar
• Gounaris E, Blatner NR, Dennis K, et al. (2009). T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res, 69(13), 5490–5497.
   PubMed Web of Science ®Google Scholar
• Grady WM, Myeroff LL, Swinler SE, et al. (1999). Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res, 59(2), 320–324.
   PubMed Web of Science ®Google Scholar
• Greten FR, Eckmann L, Greten TF, et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3), 285–296.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15(2), 103–113.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.
   Google Scholar
• Grivennikov SI, Karin M. (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 21(1), 11–19.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Wang K, Mucida D, et al. (2012). Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 491(7423), 254–258.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Kelleher CC, Harris TJ, et al. (2007). LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest, 117(11), 3383–3392.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
   PubMed Web of Science ®Google Scholar
• He G, Karin M. (2011). NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res, 21(1), 159–168.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Miyazono K, ten Dijke P. (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 390(6659), 465–471.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057–1061.
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Liang Y, Tyznik AJ, et al. (2004). Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity, 21(2), 267–277.
   PubMed Web of Science ®Google Scholar
• Huang CT, Workman CJ, Flies D, et al. (2004). Role of LAG-3 in regulatory T cells. Immunity, 21(4), 503–513.
   PubMed Web of Science ®Google Scholar
• Hughes JM, Weill H. (1991). Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. Br J Ind Med, 48(4), 229–233.
   PubMedGoogle Scholar
• Ikeda H, Old LJ, Schreiber RD. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13(2), 95–109.
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Lu LF, Rudensky AY. (2012). Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol, 30, 531–564.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. (2006). Fibroblasts in cancer. Nat Rev Cancer, 6(5), 392–401.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 95(13), 7556–7561.
   PubMed Web of Science ®Google Scholar
• Karin M. (2006). NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog, 45(6), 355–361.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749–759.
   PubMed Web of Science ®Google Scholar
• Khansari N, Shakiba Y, Mahmoudi M. (2009). Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov, 3(1), 73–80.
   PubMedGoogle Scholar
• Khattri R, Cox T, Yasayko SA, Ramsdell F. (2003). An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 4(4), 337–342.
   PubMed Web of Science ®Google Scholar
• Kim JM, Rasmussen JP, Rudensky AY. (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 8(2), 191–197.
   PubMed Web of Science ®Google Scholar
• Kim KS, Hong SW, Han D, et al. (2016). Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science, 351(6275), 858–863.
   PubMed Web of Science ®Google Scholar
• Kimelman D, Kirschner M. (1987). Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell, 51(5), 869–877.
   PubMed Web of Science ®Google Scholar
• Klein L, Kyewski B, Allen PM, Hogquist KA. (2014). Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol, 14(6), 377–391.
   PubMed Web of Science ®Google Scholar
• Kretschmer K, Apostolou I, Hawiger D, et al. (2005). Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 6(12), 1219–1227.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 15(3), 178–196.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, et al. (2006). IL-23 promotes tumour incidence and growth. Nature, 442(7101), 461–465.
   PubMed Web of Science ®Google Scholar
• Lathrop SK, Bloom SM, Rao SM, et al. (2011). Peripheral education of the immune system by colonic commensal microbiota. Nature, 478(7368), 250–254.
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, et al. (2007). Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26(3), 371–381.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol, 14, 233–258.
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Flavell RA. (2007). T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity, 26(5), 579–591.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang P, Li J, et al. (2008). A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol, 9(6), 632–640.
   PubMed Web of Science ®Google Scholar
• Long M, Park SG, Strickland I, et al. (2009). Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity, 31(6), 921–931.
   PubMed Web of Science ®Google Scholar
• Loser K, Apelt J, Voskort M, et al. (2007). IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol, 179(1), 365–371.
   PubMed Web of Science ®Google Scholar
• Lu SL, Herrington H, Reh D, et al. (2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev, 20(10), 1331–1342.
   PubMed Web of Science ®Google Scholar
• Mantel PY, Ouaked N, Ruckert B, et al. (2006). Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol, 176(6), 3593–3602.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.
   PubMed Web of Science ®Google Scholar
• Markowitz S, Wang J, Myeroff L, et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 268(5215), 1336–1338.
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Roberts AB. (1996). Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev, 7(1), 93–102.
   PubMedGoogle Scholar
• Massague J, Chen YG. (2000). Controlling TGF-beta signaling. Genes Dev, 14(6), 627–644.
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, et al. (2015). Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 15(8), 457–472.
   PubMed Web of Science ®Google Scholar
• Mittal P, St Rose MC, Wang X, et al. (2015). Tumor-unrelated CD4 T cell help augments CD134 plus CD137 dual costimulation tumor therapy. J Immunol, 195(12), 5816–5826.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19, 683–765.
   PubMed Web of Science ®Google Scholar
• Moore RJ, Owens DM, Stamp G, et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5(7), 828–831.
   PubMed Web of Science ®Google Scholar
• Moses HL, Yang EY, Pietenpol JA. (1990). TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 63(2), 245–247.
   PubMed Web of Science ®Google Scholar
• Nicholl MB, Ledgewood CL, Chen X, et al. (2014). IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine, 70(2), 126–133.
   PubMed Web of Science ®Google Scholar
• Nishio J, Honda K. (2012). Immunoregulation by the gut microbiota. Cell Mol Life Sci, 69(21), 3635–3650.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13(5), 715–725.
   PubMed Web of Science ®Google Scholar
• Oshima M, Dinchuk JE, Kargman SL, et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809.
   PubMed Web of Science ®Google Scholar
• Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L. (2006). Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity, 25(2), 249–259.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4), 252–264.
   PubMed Web of Science ®Google Scholar
• Perez-Villar JJ, Whitney GS, Bowen MA, et al. (1999). CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol, 19(4), 2903–2912.
   PubMed Web of Science ®Google Scholar
• Rebouissou S, Amessou M, Couchy G, et al. (2009). Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 457(7226), 200–204.
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. (2010). Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med, 49(11), 1603–1616.
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Rasmussen JP, Chi EY, et al. (2008). Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity, 28(4), 546–558.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. (2000). Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 101(5), 455–458.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155(3), 1151–1164.
   Google Scholar
• Salomon B, Lenschow DJ, Rhee L, et al. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 12(4), 431–440.
   PubMed Web of Science ®Google Scholar
• Schmidt-Supprian M, Tian J, Grant EP, et al. (2004). Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci USA, 101(13), 4566–4571.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. (2011). Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024), 1565–1570.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. (2003). T cell anergy. Annu Rev Immunol, 21, 305–334.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res, 1(1), 32–42.
   PubMed Web of Science ®Google Scholar
• Sen G, Bikah G, Venkataraman C, Bondada S. (1999). Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur J Immunol, 29(10), 3319–3328.
   PubMed Web of Science ®Google Scholar
• Shattuck-Brandt RL, Varilek GW, Radhika A, et al. (2000). Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(−/−) mice. Gastroenterology, 118(2), 337–345.
   PubMed Web of Science ®Google Scholar
• Singh A, Singh A, Bauer SJ, et al. (2016). Genetic deletion of TNFalpha inhibits ultraviolet radiation-induced development of cutaneous squamous cell carcinomas in PKCepsilon transgenic mice via inhibition of cell survival signals. Carcinogenesis, 37(1), 72–80.
   PubMed Web of Science ®Google Scholar
• Starr TK, Jameson SC, Hogquist KA. (2003). Positive and negative selection of T cells. Annu Rev Immunol, 21, 139–176.
   PubMed Web of Science ®Google Scholar
• Street SE, Cretney E, Smyth MJ. (2001). Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 97(1), 192–197.
   Google Scholar
• Swann JB, Smyth MJ. (2007). Immune surveillance of tumors. J Clin Invest, 117(5), 1137–1146.
   PubMed Web of Science ®Google Scholar
• Tai X, Cowan M, Feigenbaum L, Singer A. (2005). CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol, 6(2), 152–162.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Wu LW, Grivennikov SI, et al. (2015). A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature, 519(7541), 57–62.
   PubMed Web of Science ®Google Scholar
• Thiery JP. (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol, 15(6), 740–746.
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Pflanz S, Kastelein RA. (2003). The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity, 19(5), 641–644.
   PubMed Web of Science ®Google Scholar
• Turnis ME, Sawant DV, Szymczak-Workman AL, et al. (2016). Interleukin-35 limits anti-tumor immunity. Immunity, 44(2), 316–329.
   PubMed Web of Science ®Google Scholar
• Vang KB, Yang J, Mahmud SA, et al. (2008). IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol, 181(5), 3285–3290.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 29, 235–271.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. (2008). How regulatory T cells work. Nat Rev Immunol, 8(7), 523–532.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Kuchroo VK. (2012). IL-12 family cytokines: immunological playmakers. Nat Immunol, 13(8), 722–728.
   PubMed Web of Science ®Google Scholar
• Wang CY, Eshleman JR, Willson JK, Markowitz S. (1995). Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Res, 55(21), 5101–5105.
   PubMed Web of Science ®Google Scholar
• Wang K, Karin M. (2015). Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res, 128, 173–196.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu JQ, Liu Z, et al. (2013). Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol, 190(5), 2415–2423.
   PubMed Web of Science ®Google Scholar
• Wildin RS, Smyk-Pearson S, Filipovich AH. (2002). Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet, 39(8), 537–545.
   Google Scholar
• Williams LM, Rudensky AY. (2007). Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol, 8(3), 277–284.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322(5899), 271–275.
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res, 19(2), 156–172.
   PubMed Web of Science ®Google Scholar
• Yang X, Letterio JJ, Lechleider RJ, et al. (1999). Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J, 18(5), 1280–1291.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. (2004). The STATs of cancer–new molecular targets come of age. Nat Rev Cancer, 4(2), 97–105.
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7(1), 41–51.
   PubMed Web of Science ®Google Scholar
• Yusuf N, Nasti TH, Katiyar SK, et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res, 68(10), 3924–3930.
   PubMed Web of Science ®Google Scholar
• Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. (2006). Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood, 107(10), 3925–3932.
   PubMed Web of Science ®Google Scholar
• Zheng SG, Wang JH, Gray JD, et al. (2004). Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: The role of IL-2, TGF-beta, and IL-10. J Immunol, 172(9), 5213–5221.
   PubMed Web of Science ®Google Scholar